|
Showing 1 - 5 of
5 matches in All Departments
This book provides an overview of the key developments in both
acute lymphocytic leukemia and acute myeloid leukemia with a
comprehensive guide to the epidemiology, pathogenesis, etiology,
clinical manifestations, classification, diagnosis, and staging as
well as the most recent developments in the therapeutic landscape
for acute leukemia. The Handbook of Acute Leukemia offers readers a
key resource into the future outlook for patients with leukemia and
is edited and authored by internationally renowned experts in the
field. Leukemia is cancer of the white blood cells and acute
leukemia means the condition progresses rapidly and aggressively,
requiring immediate treatment. Acute leukemia is classified
according to the type of white blood cells that are affected:
either lymphocytes and myeloid cells.
150 years after the first description of the clinical picture of
"white blood" and the introduction of the term "leukemia" by R.
Virchow it appears, that the leukemias, and the acute leukemias in
particular, serve as an impressive example for the major
improvements that have been achieved in the treatment but also in
the understand ing of the biology of malignant dis orders. The
international symposia "Acute Leukemia" which are held at Munster
since 1986 have developed into an interna tional forum to review
the current progress and the future perspectives of leukemia
research and therapy at a high scientific and clinicallevel. Since
the possibility for active participation in these symposia is
somewhat restricted we are glad to have the opportunity to extend
the information that was presented at the symposium "Acute
Leukemias V - Experimental Approaches and Management of Refractory
Disease" which was held from February 27 to March 2, 1994 to a
broader audience of basic scientists and clinicians. This meeting
was especiaIly designed to discuss experimen tal approaches and the
management of refractory disease which allows to evaluate new
experimental therapies on the basis of preclinical studies."
The 6th volume of the book series Acute Leukemias presents both
therapeutic and prognostic updates of the most recent results of
major multicenter clinical trials. Additional chapters report on
new trends in leucemia cell biology, the monitoring of minimal
residual disease and secondary leucemias as well as new
antileucemic drugs, antimicrobial strategies and the use of
cytocines. Acute Leukemias VI provides a new update on the rapid
progress being made internationally concerning leucemic diseases.
Acute leukemia a quite homogenous disease failed to break through
the sound barriere of when untreated reveals a substantial hetero
unsatisfactory cure rates even in special sub geneity in its
response to therapy. While cure groups. While new protocols
including more is achieved in a certain proportion of pa effective
supportive care show some increase tients other cases prove to be
highly resis in the initial response rates and certain im tant. The
curability is superior in acute provements in the long-term
results, no ben lymphoblastic (ALL) than in acute myeloid eficial
effect on the relapse rate during the (AML) leukemia and - within
both type- first 1 Y2 years emerged from any of these higher in
children as compared to adults. regimens. Thus, high chances for
cure are The two age groups and cell types can be presently
restricted to children with ALL further subdivided into prognostic
groups and to lesser proportions children with by special
diagnostic features. Thus, in AML and adults with ALL and AML.
|
Tumor Aneuploidy (Paperback)
Thomas Buchner; Assisted by Michael Andreeff, B. Barlogie; Edited by Clara D. Bloomfield, Wolfgang Hiddemann; Assisted by …
|
R1,526
Discovery Miles 15 260
|
Ships in 10 - 15 working days
|
Chromosome abnormalities of cancer cells have been recognized for a
long time, and have generally proven to be a highly specific marker
ofmalignancy. The contri- butions collected in this book, "Tumor
Aneuploidy", cover several major aspects of present knowledge
conceming the occurrence and clinical significance of chromo- some
abnormalities as delineated by karyotype analyses or measurements
of the cellular DNA content. Certain non-random clonal chromosome
losses, deletions and translocations ap- pear to represent primary
genetic lesions of malignancies and reflect their clonal origin.
Secondary intraneoplastic genetic evolution is suggested by major
clonal ab- normalities of chromosome number and cellular DNA
content. Both types of ge- netic changes have been reaching great
relevance in cancer medicine, today. Although the Philadelphia
chromosome was first discovered in chronic myelo- cytic leukemia
(CML), by Nowell and Hungerford in 1960, new banding techniques
developed in the 1970's were needed to identity this abnormality as
a translocation between chromosomes 9 and 22 (t(9; 22)). Soon
thereafter, further non-random translocations were detected and
attributed to special diseases like t(8; 21) and t(15; 17) to acute
myeloid leukemias (AML) and t(9; 22), t(4; 11), t(8; 14) to acute
lymphoblastic leukemia (ALL).
|
You may like...
Loot
Nadine Gordimer
Paperback
(2)
R398
R330
Discovery Miles 3 300
|